Pulse Therapeutics, a medical device company known as Euphrates Vascular, specializes in utilizing nanotechnology to optimize blood flow and treat distal vessel occlusions in various conditions. Their innovative and groundbreaking product, the Pulse NanoMED™ System, is a nanoscale interventional tool designed to extend beyond the reach of traditional wires and catheters. By utilizing iron-oxide nanoparticles under the influence of an external rotating magnet, the NanoMED™ System can effectively disrupt and clear distal vessel occlusions that are otherwise unreachable with existing treatments.

The company focuses on three key areas: Acute Ischemic Stroke (AIS), Peripheral Artery Disease (PAD), and ST Elevated Myocardial Infarction (STEMI). Their goal is to restore blood flow and achieve Total Tissue Reperfusion (TTR), improving patient outcomes and reducing the risk of complications. With their disruptive technology, Pulse Therapeutics aims to revolutionize the field of vascular occlusion treatment, providing better health economics and ultimately saving lives